FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Save November 30, 2023 5:00 pm ET Acceptance based on results from ...
Treatment options for patients with metastatic breast cancer are severely limited and ultimately rely on palliative care representing an unmet clinical need. Pr...
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105-117. doi:10.1016/S0140-6736(22)02420-5 FDA grants regular approval to...
FDA Grants Fast Track Designation to Deltacel Plus Radiation for Pretreated Metastatic NSCLC Fast track designation has been granted by the FDA to Deltacel (KB-GDT-01) with low-dose radiation therapy to potentially treat patients with metastatic non–small cell lung cancer (NSCLC...
FDA fast track designation has been granted to cell-based immunotherapy Bria-IMT for the treatment of patients with metastatic breast cancer.
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clin
The FDA has granted a priority review to a new drug application for oral paclitaxel and encequidar for use in patients with metastatic breast cancer. The FDA has granted a priority review to a new drug application (NDA) for oral paclitaxel and encequidar (oral paclitaxel) for use ...
HER2+ breast cancer patients are presented with either synchronous (S-BM), latent (Lat), or metachronous (M-BM) brain metastases. However, the basis for disparate metastatic fitness among disseminated tumor cells of similar oncotype within a distal organ remains unknown. Here, employing brain meta...
et al. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer. Breast Cancer Res 26, 13 (2024). https://doi.org/10.1186/s13058-024-01768-y Download citation Received30 May 2023 Accepted09 ...
, St Vincent’s Clinical Foundation grants (M.N., D.H., P.T., and C.E.C.), an Australian Cancer Research Fund (ACRF) grant, and Suttons Family and Len Ainsworth Foundation philanthropy and Cancer Research UK core funding at the CRUK Beatson Institute (A17196). Author contributions ...